


ON THE FRONTLINE:

Immunotherapeutic Approaches in Advanced NSCLC



Provided by RMEI Medical Education, LLC.



This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

EARN UP TO 1.0 AMA PRA CATEGORY 1 CREDIT(S)TM

THURSDAY, SEPTEMBER 9, 2021

**13:15 – 14:15 MDT / 15:15 – 16:15 EDT
21:15 – 22:15 CEST**



WHO SHOULD ATTEND?

This virtual symposium is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

This program was approved by the IASLC 2021 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2021 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

INTERACTIVE PANEL-BASED FORMAT



Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Professor, Pharmacology
Chief, Medical Oncology
Associate Director, Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT



Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine
(Medical Oncology)
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT



Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology
Charles University Medical Faculty and Hradec Králové
University Hospital
Prague, Czech Republic

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be better able to:

- Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
- Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC
- Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial
- Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting

PROGRAM AGENDA

- 13:15 – 13:20 **Welcome and Introductions**
Roy S. Herbst, MD, PhD
- 13:20 – 13:35 **PANEL DISCUSSION 1 – Key Concepts in NSCLC Biomarker Testing**
All Faculty
- 13:35 – 13:55 **PANEL DISCUSSION 2 – Clinical Pearls for Frontline Immunotherapy in Advanced NSCLC**
All Faculty
- 13:55 – 14:05 **PANEL DISCUSSION 3 – IRAE Considerations for Patients with NSCLC Receiving Immunotherapy**
All Faculty
- 14:05 – 14:15 **Audience Q&A and Closing Remarks**
All Faculty

JOINT ACCREDITATION STATEMENT



JOINTLY ACCREDITED PROVIDER[™]
INTERPROFESSIONAL CONTINUING EDUCATION

Credit Designation

RMEI Medical Education, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationship for all persons in control of content before the learner engages in the education.

FEE INFORMATION

There is no fee for this educational activity. Individuals must be registered for the IASLC 2021 WCLC in order to attend this symposium.